Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Intas Pharmaceuticals...

    Intas Pharmaceuticals Completes Deal to Acquire Actavis UK,Ireland Generics Businesses From Teva

    Written by supriya Published On 2017-01-11T11:09:43+05:30  |  Updated On 11 Jan 2017 11:09 AM IST
    Intas Pharmaceuticals Completes Deal to Acquire Actavis UK,Ireland Generics Businesses From Teva

    Ahmedabad : Intas Pharmaceuticals Ltd. through its wholly-owned subsidiary Accord Healthcare Ltd. announced it has completed the deal to acquire Actavis UK Ltd. & Actavis Ireland Ltd. from Teva Pharmaceutical Industries Ltd. for an enterprise value of £603 million payable in cash. The transaction is part of the European Commission's anti-trust divestiture requirements arising from Teva's acquisition of Allergan's generics business.


    Following the completion of the acquisition, Accord strengthens its footprint in the UK and Ireland retail market to become a leading player in the industry at European level, while Intas becomes a top 20 generic player globally. The combination with Actavis UK Ltd. and Actavis Ireland gives Accord an exciting opportunity to build on its already strong position in the market, providing the Company with increased access to UK and Irish retail and hospital markets. The combination of these two high performing businesses, expands Accord's UK manufacturing presence with the addition of the GMP Barnstaple site owned by Actavis, resulting in a combined regional base revenue of more than half a billion euros per year, and a workforce of more than 1,000 employees.


    "The completion of this acquisition captures a great opportunity for growth and demonstrates Intas' commitment to greater European expansion," says Mr Binish Chudgar, Vice Chairman and Managing Director of Intas. "The joining of these two companies means we can continue our successful European operating path, which started more than a decade ago. We are a leading generics player in the UK market, with a clear plan for continued growth and development of the Barnstaple site and the Actavis team. Through our subsidiary, Accord Healthcare, we are welcoming the Actavis team into the Intas family and will ensure a smooth integration of the two businesses," Chudgar added.


    This acquisition further demonstrates Accord's commitment to UK manufacturing, adding to the recent significant investment to reinstate a facility in Newcastle. The Barnstaple plant will become one of Accord's four UK sites, ensuring the company has one of the most extensive local supply chains to service pharmacies, clinicians, hospitals and wholesalers across UK and Ireland, and into Europe.

    Accord HealthcareAcquisitionAllerganIntas PharmaceuticalsMr Binish ChudgarTeva
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya
    supriya
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok